SNG.L

Synairgen Plc
Synairgen plc - Grant of Options
22nd June 2023, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5144D
Synairgen plc
22 June 2023
 

 


Synairgen plc

('Synairgen' or the 'Company')

Grant of Options

 


Southampton, UK - 22 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 21 June 2023 the Board of Synairgen granted options ('Options') over 6,132,718 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 3.05 per cent. of the Company's issued share capital. 

Following this grant, Synairgen has 18,119,156 options in issue, representing 9.00 per cent. of the Company's issued share capital.

Certain Options were issued to Directors of the Company and Persons Discharging Managerial Responsibilities ('PDMR'):

Options issued      21 June 2023

Total options

Ordinary shares

Total interest

Percentage holding of fully diluted share capital

Directors






Richard Marsden1

496,000

2,819,178

995,771

3,814,949

1.74%

Dr. Phillip Monk

480,000

2,159,771

423,934

2,583,705

1.18%

John Ward

480,000

2,259,140

734,092

2,993,232

1.36%

PDMRs






Jody Brookes

480,000

1,323,590

-

1,323,590

0.60%

Richard Francis

480,000

1,108,636

-

1,108,636

0.51%

Richard Hennings

480,000

1,237,568

-

1,237,568

0.56%

Gareth Walters

480,000

1,115,779

-

1,115,779

0.51%

 

1.   Richard Marsden's shareholding includes 184,821 shares held in his pension plan.

 

The Options are issued under the Company's Long Term Incentive Plan and are exercisable up to 20 June 2033, subject to the achievement of appropriate performance criteria which match the criteria for the 2022 award as set out on page 23 of the 2022 annual report.

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

 

finnCap (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

 

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com  

Tel: +1 516-606-6545

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Richard Marsden

2.

Reason for notification

a)

Position / status

Chief Executive Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans

c)

Price(s) and volume(s)

496,000 Options awarded

Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

21 June 2023

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Dr Phillip Monk

2.

Reason for notification

a)

Position / status

Chief Scientific Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans

c)

Price(s) and volume(s)

480,000 Options awarded

Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

21 June 2023

f)

Place of the transaction

Outside a trading venue

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

John Ward

2.

Reason for notification

a)

Position / status

Chief Financial Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans 

c)

Price(s) and volume(s)

 480,000 Options awarded

 Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

21 June 2023

f)

Place of the transaction

Outside a trading venue

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Jody Brookes

2.

Reason for notification

a)

Position / status

Head of Clinical Operations

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans

c)

Price(s) and volume(s)

 480,000 Options awarded

 Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

21 June 2023

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Richard Francis

2.

Reason for notification

a)

Position / status

Head of CMC and Quality

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans 

c)

Price(s) and volume(s)

 480,000 Options awarded

 Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

21 June 2023

f)

Place of the transaction

Outside a trading venue

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Richard Hennings

2.

Reason for notification

a)

Position / status

Chief Commercial Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans 

c)

Price(s) and volume(s)

 480,000 Options awarded

 Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

21 June 2023

f)

Place of the transaction

Outside a trading venue

 

1.

Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')

a)

Name

Gareth Walters

2.

Reason for notification

a)

Position / status

Chief Regulatory Officer

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Synairgen plc

b)

LEI

213800IMMTOPPDF8HD24

4.

Details of the transaction(s):

a)

Description of the financial instrument

 

Identification code

 

Options over ordinary shares of 1p each

 

 

GB00B0381Z20

b)

Nature of the transaction

Award of Options under the Company's share plans 

c)

Price(s) and volume(s)

 480,000 Options awarded

 Exercise price of one pence

d)

Aggregated information

Aggregated volume Price

n/a

e)

Date of the transaction

21 June 2023

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAEKFAFNDEAA ]]>
TwitterFacebookLinkedIn